MetaVia is trading 6.44% up at $1.52 in pre-market on October 14, 2026; the catalyst is unconfirmed. - On October 13, MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer, citing her clinical-development experience. - The announcement noted expected fourth-quarter data from the DA-1726 trial. - Broader futures were modestly higher, but available reporting does not link them or Browne’s appointment to the move.